

In 2013, 1,230,000 new cases were diagnosed, and 700,000 people died of cancer related diseases. Over 2.5 million adults suffer from Cancer related disease in India. Stomach cancer is the top killer for the population as a whole, breast cancer among women, and lung cancer among men.

Tobacco related cancer account for nearly one third of all cancers in India, predominantly head and neck, lung, and esophageal cancers. India women most commonly suffer from cervical, uteri and breast cancer. The incidence of breast cancer in India is increasing, with an estimated 145,000 new cases diagnosed (2012). About 17% of the world's breast cancer population are in India.

Unfortunately, Indian patients may not seek early diagnosis. More than 70% of all cancers in India are found when the disease is so advanced that treatment is much less effective.


Lastly, Cancer incidence in India is estimated to increase from 90 per 100,000 population to 130-170 per 100,000 population by 2020. Currently, cancer treatment market in India is estimated at USD 1.7-2.0 billion, in 2015.

Our Sites and Investigators

Our access to the most prominent oncology sites and investigators ensures a large and diverse patient pool along with the most up-to-date lines of medical treatment. We ensure that clinical trials are conducted according to ICH-GCP guidelines meet the highest standards of ethics and integrity. Other common oncology indications in India also include mouth/pharynx, esophagus, in males. Cervix, breast, mouth / oro-pharynx and esophagus, in females.

CITIES	SITES	INVESTIGATORS
Delhi/ NCR	12	35
Mumbai	11	25
Kolkata	11	20
Bangalore	10	25
Chennai	10	20
Hyderabad	10	15
Pune	8	10
Jaipur	4	5
Ahmedabad	5	8
Nagpur	3	5
Others	28	48
Total	112	216

Estimated # new cancer patients; 1.23M



INDICATION	PHASE
Adeno Carinoma	I
Breast Carcinoma	II
Pancreatic Carcinoma	III
Multiple Indication (G-CSF Support Therapy)	III
Multiple Indication (GM-CSF Support Therapy)	III

ELS experience - Oncology Studies

Excel Life Sciences (ELS) is India's premier clinical trial and site management organization with extensive regulatory and clinical trials expertise. ELS has conducted over 40 studies for FDA submission and has undergone successful FDA and EMEA audits. We lead a network of ICH-GCP compliant investigators across 30 cities. Excel Life Sciences has offices in Boston, Chicago, New Delhi, and Research Triangle Park, NC.

USA +1 – 877 – EXCELOK (877) 392 – 3565 INDIA +91 120 4022 600

E-MAIL excel@excellifesciences.com WEB SITE www.excellifesciences.com